Your browser doesn't support javascript.
loading
DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis - A narrative review from the ECNP bipolar disorders network.
Kessing, Lars Vedel; González-Pinto, Ana; Fagiolini, Andrea; Bechdolf, Andreas; Reif, Andreas; Yildiz, Aysegül; Etain, Bruno; Henry, Chantal; Severus, Emanuel; Reininghaus, Eva Z; Morken, Gunnar; Goodwin, Guy M; Scott, Jan; Geddes, John R; Rietschel, Marcella; Landén, Mikael; Manchia, Mirko; Bauer, Michael; Martinez-Cengotitabengoa, Monica; Andreassen, Ole A; Ritter, Philipp; Kupka, Ralph; Licht, Rasmus W; Nielsen, René Ernst; Schulze, Thomas G; Hajek, Tomas; Lagerberg, Trine Vik; Bergink, Veerle; Vieta, Eduard.
Affiliation
  • Kessing LV; Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen, Department O, University Hospital of Copenhagen, Rigshospitalet, and University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address: lars.vedel.kessing@regionh.dk.
  • González-Pinto A; Department of Psychiatry, BIOARABA, Hospital Universitario de Alava, UPV/EHU. CIBERSAM, Vitoria, Spain.
  • Fagiolini A; Department of Mental Health and Sensory Organs, University of Siena School of Medicine, Siena, Italy.
  • Bechdolf A; Department of Psychiatry, Psychotherapy and Psychosomatics, Vivantes Hospital am Urban and Vivantes Hospital im Friedrichshain/Charite Medicine Berlin and University of Cologne, Germany.
  • Reif A; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.
  • Yildiz A; Department of Psychiatry, Dokuz Eylül University, Izmir, Turkey.
  • Etain B; Université de Paris and INSERM UMRS 1144, Paris, France.
  • Henry C; Department of Psychiatry, Service Hospitalo-Universitaire, GHU Paris Psychiatrie & Neuroscience, Paris, France.
  • Severus E; Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Reininghaus EZ; Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria.
  • Morken G; Department of Psychiatry, St Olav University Hospital & Department of Mental Health, Norwegian University of Science and Technology - NTNU, Trondheim, Norway.
  • Goodwin GM; Department of Psychiatry, University of Oxford and Oxford Health NHS Foundation Trust, Oxford, United Kingdom.
  • Scott J; Institute of Neuroscience, Newcastle University, Newcastle, United Kingdom.
  • Geddes JR; Department of Psychiatry, University of Oxford and Oxford Health NHS Foundation Trust, Oxford, United Kingdom.
  • Rietschel M; Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Landén M; Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
  • Manchia M; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italia; Department of Pharmacology, Dalhousie University, Halifax, NS, Canada.
  • Bauer M; Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Martinez-Cengotitabengoa M; Osakidetza, Basque Health Service. Bioaraba, Health Research Institute, University of the Basque Country, UPV/EHU, Spain; Psychology Clinic of East Anglia. 68 Bishopgate, NR1 4AA, Norwich, United Kingdom.
  • Andreassen OA; NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Ritter P; Department of Psychiatry, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
  • Kupka R; Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
  • Licht RW; Aalborg University Hospital, Psychiatry, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Nielsen RE; Aalborg University Hospital, Psychiatry, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Schulze TG; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Germany.
  • Hajek T; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada; National Institute of Mental Health, Klecany, Czech Republic.
  • Lagerberg TV; NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Bergink V; Department of Psychiatry and Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine and Mount Sinai, New York, USA; Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Vieta E; Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
Eur Neuropsychopharmacol ; 47: 54-61, 2021 06.
Article de En | MEDLINE | ID: mdl-33541809
ABSTRACT
This narrative review summarizes and discusses the implications of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 and the upcoming International Classification of Diseases (ICD)-11 classification systems on the prevalence of bipolar disorder and on the validity of the DSM-5 diagnosis of bipolar disorder according to the Robin and Guze criteria of diagnostic validity. Here we review and discuss current data on the prevalence of bipolar disorder diagnosed according to DSM-5 versus DSM-IV, and data on characteristics of bipolar disorder in the two diagnostic systems in relation to extended Robin and Guze criteria 1) clinical presentation, 2) associations with para-clinical data such as brain imaging and blood-based biomarkers, 3) delimitation from other disorders, 4) associations with family history / genetics, 5) prognosis and long-term follow-up, and 6) treatment effects. The review highlights that few studies have investigated consequences for the prevalence of the diagnosis of bipolar disorder and for the validity of the diagnosis. Findings from these studies suggest a substantial decrease in the point prevalence of a diagnosis of bipolar with DSM-5 compared with DSM-IV, ranging from 30-50%, but a smaller decrease in the prevalence during lifetime, corresponding to a 6% reduction. It is concluded that it is likely that the use of DSM-5 and ICD-11 will result in diagnostic delay and delayed early intervention in bipolar disorder. Finally, we recommend areas for future research.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble bipolaire Type d'étude: Diagnostic_studies / Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Eur Neuropsychopharmacol Sujet du journal: PSICOFARMACOLOGIA Année: 2021 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble bipolaire Type d'étude: Diagnostic_studies / Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Eur Neuropsychopharmacol Sujet du journal: PSICOFARMACOLOGIA Année: 2021 Type de document: Article
...